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Abstract 22 
 23 
To elucidate the mode of viral persistence in primate lentivirus-infected individuals during 24 
combination antiretroviral therapy (cART), four simian immunodeficiency virus 25 
(SIV)239-infected monkeys were treated with cART for 1 year. The viral env genes prepared 26 
from total RNA extracted from the mesenteric lymph nodes by single genome amplification 27 
were assessed at the completion of therapy. Analyses of nucleotide substitution and 28 
phylogeny revealed no viral evolution during cART. 29 
30 
  3 
  Combination anti-retroviral therapy (cART) has transformed human 31 
immunodeficiency virus (HIV) infection from incurable to a manageable disease. It 32 
suppresses the viral burden in patients to undetectable levels (14, 16, 27), lowers the chance 33 
of viral transmission (28), increases the number of CD4+ T lymphocytes (14, 16), 34 
reconstitutes immunity (4, 24, 38), and extends the life expectancy of patients (1). However, 35 
cART does not cure patients due to its inability to eradicate the virus from infected 36 
individuals (7), suggesting the existence of a viral reservoir that is refractory to cART. Its 37 
identification and eradication are, therefore, requisites for a functional cure for acquired 38 
immunodeficiency syndrome (AIDS). To establish a strategy for eradication of the HIV 39 
reservoir, the mechanism of persistence of the virus must be elucidated. Two mechanisms of 40 
viral persistence have been proposed: one is ongoing cycles of viral replication despite the 41 
presence of antivirals (37), and the other is provirus integration into long-lived cells (32). 42 
Whereas preceding studies concerning this issue have been extensively conducted employing 43 
clinical specimens from HIV-1-infected patients, including plasma, peripheral blood 44 
mononuclear cells, and gut-associated lymphatic tissues (2, 11, 23), lymph nodes, which are 45 
epicenters of virus replication in infected individuals not undergoing therapy (10, 25, 26), 46 
have been subjected to scrutiny only rarely. In animal models of cART, in particular the 47 
simian immunodeficiency virus (SIV)/macaque model, which allows for systemic 48 
examination, the identification of the viral reservoir and the mechanism of viral holding have 49 
not been studied in detail. 50 
To elucidate how the virus is maintained during cART in an animal model of 51 
anti-HIV chemotherapy, we administered a combination of nucleotide/nucleoside reverse 52 
transcriptase inhibitors (azidothymidine [AZT], lamivudine [3TC], and tenofovir disoproxil 53 
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fumarate [TDF]) and protease inhibitors (lopinavir [LPV] with ritonavir [RTV]) to four 54 
SIV239-infected rhesus macaques for 1 year (18). Although the plasma viral RNA loads of 55 
the animals were suppressed to below the assay detection limit during the period of 56 
chemotherapy, systemic analysis conducted at the completion of the therapy revealed viral 57 
RNA present in lymphatic tissues, especially in mesenteric and splenic lymph nodes (MLN 58 
and SLN, respectively) at high titers. Reasoning that any possible mode(s) of viral 59 
persistence should be in operation in tissues with high levels of viral RNA expression, we 60 
investigated viral genes in these tissues. 61 
It is expected that viral genes accumulate nucleotide substitutions in proportion to 62 
time post-infection in individuals not undergoing therapy due to continuous virus replication 63 
mediated by the error-prone viral reverse transcriptase. Such mutation rates have indeed been 64 
observed in the V3 loop of env, p17 of gag (20), and C2-C5 region of env (30) in HIV-1 65 
infected patients as well as in the env gene from monkeys experimentally infected with SIV 66 
(5, 19). We hypothesized that viral genes would accumulate mutations if the virus was 67 
continuously replicating in the reservoir despite the presence of antivirals. 68 
First, to ascertain whether such accumulation of mutations took place to a 69 
detectable magnitude in our experimental system, SIV239, a molecularly cloned virus, was 70 
used to infect macaques for 1 year, and we periodically sampled viral genes from the 71 
untreated control animal (MM521). To reveal ongoing expression of viral genes at sampling, 72 
total RNA was extracted from plasma samples collected at 8, 18, 42, and 68 weeks 73 
post-infection (wpi) and examined. Single genome amplification (SGA) (29) was used to 74 
amplify present viral genes and to avoid selective amplification of a particular genotype or 75 
recombination between genotypes during polymerase chain reaction (PCR). Using nested 76 
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PCR, we amplified the entire env gene, which accumulates nucleotide substitutions in the 77 
greatest numbers, following reverse transcription of cDNA from the extracted RNA. The 78 
initial cycles of PCR were carried out utilizing the following primers: forward, SIV20F 79 
(5’-ctc cag gac tag cat aaa tgg-3’); reverse, SHenv9R (5’-ggg tat cta aca tat gcc tc-3’). 80 
Successive PCR cycles were run with the following primers: forward, SIV21F (5’-ctc tct cag 81 
cta tac cgc cc-3’); reverse, SHenv8R (5’-gcc ttc ttc ctt ttc taa g-3’). The PCR products from 82 
an average of 12 independent reactions per time point were directly subjected to sequencing. 83 
We computed the number of mutations in each SGA clone obtained from plasma 84 
samples of an untreated monkey (MM521) through a comparison with that of the inoculum 85 
virus (Fig. 1). A linear relationship with a coefficient of 1.25 × 10-4 (r2 = 0.8503, p < 0.0001; 86 
GraphPad Prism, La Jolla, CA, USA) was revealed between the number of mutations in the 87 
SGA clones and the time post-infection. Using the coefficient, the cumulative mutations per 88 
annum was determined to be 6.5 × 10-3 substitutions/site/year, a comparable figure to those of 89 
SIV and HIV reported previously (9 × 10-3 (5, 19) and 6.0 × 10-3 (29) substitutions/site/year, 90 
respectively). The accuracy of the “molecular clock” in our experimental setting prompted us 91 
to examine viral RNA extracted from the lymph nodes of animals that underwent cART for 1 92 
year. 93 
Total RNA was extracted from the MLN of four treated animals and one untreated 94 
animal as well as the SLN of one of the treated animals (MM530) at the completion of the 95 
observation period and used as template for PCR; the products were subjected to sequence 96 
analysis as described above. On average, 10 sequences were obtained from each sample (Fig. 97 
2A and Table). The number of mutations observed in the env gene from MM521 (untreated) 98 
was, on average, 25 of 2700 bases. In contrast, the number in treated animals was on average 99 
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1.5 of 2700 bases (Table). The difference in the number of mutations in env between the 100 
plasma and MLN samples at 68 wpi (at necropsy) in the untreated animal, MM521, was 101 
statistically insignificant (p > 0.05; Fig. 2A), justifying our comparison of these two distinct 102 
anatomical compartments. Thus, we proceeded to compare the substitution numbers in the 103 
plasma at 8 wpi, immediately before the onset of cART, with those from the lymph nodes of 104 
animals treated with cART at necropsy (61-65 wpi). Nucleotide substitutions in the env gene 105 
in both plasma and the MLN of the untreated animal (MM521) at 68 wpi increased compared 106 
to that in plasma at 8 wpi (p < 0.0001). In contrast, those in the MLN of treated animals at the 107 
completion of cART were unchanged (MM528 and SLN of MM530) or decreased 108 
significantly (MM491, MM499, and MLN of MM530) (Fig. 2A). The results indicated that 109 
virus did not accumulate further mutations beyond those obtained by 8 wpi. 110 
As the samples were collected from animals at various time points post-infection, 111 
the numbers depicted in Fig. 2A were converted to substitutions/site/year (Fig. 2B) for 112 
further analysis. Comparison of the number of viral mutations in plasma at 8 wpi (median, 113 
5.9 × 10-3 substitutions/site/year) with that in the MLN (median, 7.2 × 10-3 114 
substitutions/site/year) in the untreated animal, MM521, indicated no statistical difference (p 115 
= 0.6265), as predicted by the analysis in Fig. 2A. Next, we compared the numbers in 116 
animals that underwent chemotherapy. At 8 wpi, the treated animals were equivalent to 117 
MM521 (an untreated animal) in terms of therapeutic status, since cART was started after 118 
sample collection at 8 wpi. Not unexpectedly, there was no statistically significant difference 119 
in plasma number between the untreated and treated animals (MM491, 8.5×10-3; MM499, 120 
9.8×10-3; MM528, 1.6×10-2; MM530, 8.5×10-3; and MM521, 5.9×10-3 substitutions/site/year), 121 
except for MM528 (p = 0.0048 compared to those from untreated animal). In contrast, the 122 
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mutations per annum in the lymph nodes of treated animals collected at necropsy (median, 123 
3.4 × 10-4 substitutions/site/year) were significantly lower than those in the plasma of the 124 
animals at 8 wpi (median, 9.8 × 10-3 substitutions/site/year) (p < 0.0001). The number of 125 
mutations per year in lymph nodes between untreated and treated macaques was also 126 
significantly different (p < 0.0001). This supports the hypothesis that ongoing viral 127 
replication contributed little, if anything, to viral persistence during cART. 128 
Examination of the nucleotide substitution numbers did not indicate discernible de 129 
novo virus replication during cART. Therefore, we next investigated continuous viral 130 
replication during cART through phylogenetic analysis of viral env clones. Clones were 131 
obtained from the untreated animal (derived from plasma at 8, 18, 42, and 68 wpi and from 132 
MLN) and from one of the treated animals (derived from plasma at 8 wpi and MLN at 133 
necropsy) (Figs. 3 and S). To illustrate the accumulation and specific sites of mutations, 134 
Highlighter plot analysis (<www.hiv.lanl>) was also performed. Phylogenetic analysis of the 135 
viral genes from the untreated animal revealed that i) env clones from plasma exhibited 136 
increasing genetic distance from the inoculum virus with time, ii) clones obtained at a given 137 
time point branched out of the one immediately before, a clear demonstration of viral 138 
evolution, and iii) clones from the lymph node formed a cluster with those from plasma 139 
collected at the same time. In contrast, clones from treated animals, regardless of the tissue 140 
origin or time point, formed a cluster with clones derived from plasma of the untreated 141 
animal at 8 wpi and the inoculum virus (Figs. 3 and S). The results of the Highlighter plot 142 
analysis were consistent with those of the phylogenetic analysis. These results clearly 143 
demonstrated that viral evolution did not take place in SIV239-infected rhesus macaques 144 
during cART. Analysis of the env genes in the peripheral blood mononuclear cells and 145 
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gut-associated lymphatic tissues obtained from HIV-1 patients in cART also found no 146 
evidence of de novo viral replication (11). 147 
In contrast, other studies have reported continuous virus replication during 148 
combined chemotherapy (2, 37). One possible explanation of this discrepancy is the thorough 149 
suppression of the plasma viral burden, < 20 copies/mL at necropsy that was achieved in this 150 
study (18). De novo virus replication was detected in HIV-1 patients whose plasma viral 151 
RNA burdens ranged from 20 to 400 copies/mL, but not in those with less than 20 copies/mL 152 
(15). Our findings also indicate that the cART regimen we employed (18) was robust enough 153 
to halt viral evolution nearly completely in animals. 154 
Our sample size, an average of 10 sequences from each specimen, conceivably 155 
limited our ability to detect minor populations with signs of ongoing replication. An analysis 156 
of four animals, however, did not reveal the genotypes detailed in the current study. 157 
Therefore, while our results cannot rule out possible de novo viral replication during cART, 158 
the data indicate that it is not a major mode of viral persistence in individuals whose virus 159 
replication levels are thoroughly suppressed by cART. 160 
The locations of other potential viral reservoirs, in addition to resting CD4+ T 161 
lymphocytes, an already established HIV/SIV reservoir found to be present in blood (6, 8, 9, 162 
13), lymph nodes (6), and the spleen (31), remains elusive. While the cART regimen we 163 
developed suppressed viral RNA levels nearly completely in the circulation and fairly well in 164 
effector sites, such as the gastrointestinal tract and lung, viral RNA expression levels in 165 
lymph nodes were not contained effectively (18), suggesting that the viral reservoir consists 166 
of cells present in lymph nodes. We also detected CD3-positive cells, most likely CD4+ T 167 
lymphocytes, expressing Nef protein in the follicles of the MLN of an SIV-infected animal 168 
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that exhibited viral rebound upon cessation of cART (18). Based on their location, these 169 
might be Tfh cells, which are of the memory phenotype (21, 22, 36). The results of the 170 
current study have further narrowed the location of the viral reservoir from our previous 171 
study (18) to cells with longer half-lives, which retain provirus for at least 1 year. Since 172 
resting CD4+ T cells possess long half-lives (33), these cells satisfy this criterion for a viral 173 
reservoir during cART. It is conceivable that resting CD4+ T cells functioned as the 174 
predominant viral reservoir in the SIV239/rhesus macaque model for patients on cART 175 
employed in our study, as in preceding studies concerning the issue in the context of HIV and 176 
SIV infections. 177 
Lymph nodes serve as a major HIV reservoir throughout the course of infection 178 
without intervention by cART (10, 25, 26). During clinical latency, the virus persists as an 179 
intact provirus, which can produce infectious viral particles upon cell activation, in a 180 
miniscule fraction of the resting CD4+ T lymphocytes in lymph nodes (6). An extensive 181 
examination of lymph node specimens from HIV patients on cART revealed an infinitesimal 182 
amount of viral RNA-positive cells by in situ hybridization (17). Hockett et al. (17) revealed 183 
that cART lowers the number of viral RNA-positive cells in lymph nodes but that the number 184 
of viral copies in each infected cell is constant, regardless of the viral burden in the 185 
circulation, suggesting the existence of virus-infected cells actively transcribing viral genes 186 
under cART, as we found previously in the lymph nodes of SIV239-infected animals on 187 
cART (18). Taking our current observations together with those of Hockett et al. (17), the 188 
viral RNA-positive cells present in lymph nodes during cART may represent cells infected 189 
with virus prior to the initiation of cART and transcribing viral RNA from integrated provirus 190 
during therapy. 191 
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Current cART is unable to eradicate the viral reservoir; or more precisely, provirus 192 
integrated in the reservoir. Based on our results, it is important to establish strategies to target 193 
specifically long-lived cells that harbor intact provirus while unlocking the dormant state of 194 
the provirus, perhaps using histone deacetylase (3), to achieve a functional cure for AIDS. 195 
 196 
197 
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Table. Origins and numbers of env clones. 
 
*Combination anti-retroviral therapy; **single genome amplification; #mesenteric lymph node; ##splenic lymph node; ✝interpreted as a 









No. NUCLEOTIDE SUBSTITUTIONS 
MINIMUM/MAXIMUM MEAN ± SD 
MM521 UNTREATED PLASMA 8 10 1 / 8 3.3 ± 2.2 
  PLASMA 68 10 20 / 29 24.9 ± 3.2 
  MLN# 68 12 20 / 33 25.0 ± 3.4 
MM491 TREATED PLASMA 8 10 1 / 7 3.5 ± 1.8 
  MLN# 63 10 0 / 2 0.6 ± 0.8 
MM499 TREATED PLASMA 8 11 2 / 7 4.2 ± 1.7 
  MLN# 64 10 0 / 4 0.7 ± 1.3 
MM528 TREATED PLASMA 8 10 4 / 11 6.6 ± 2.4 
  MLN# 61 11     0 / 3 (12✝) 1.7 ± 1.1✝✝ 
MM530 TREATED PLASMA 8 10 2 / 8 4.0 ± 1.7 
  MLN# 65 10 0 / 4 2.1 ± 1.2 











Time-dependent accumulation of nucleotide substitutions in SIV genomes circulating in 
an infected and untreated rhesus macaque. The sequences of viral env genes in 
circulation collected at 8, 18, 42, and 68 wpi from SIV239-infected animals and an 
untreated animal (MM521) were determined. Tamura-Nei distances (34) of the 
sequences were computed with the MEGA5 software (35), and the number of 
nucleotide substitutions per site were plotted against the number of wpi. Each symbol 
represents a single genomic amplicon derived from plasma samples collected at the time 























Nucleotide substitutions in env genes from SIV239-infected animals. The number of 
mutations in env from the plasma (PL, at 8 and 68 wpi) and mesenteric lymph node 
(MLN, at 68 wpi) of an SIV-infected but untreated animal (MM521) and from the 
plasma (at 8 wpi) and MLN (at necropsy, 61, 63, 64, or 65 wpi) plus splenic lymph 
node (SLN, at necropsy, 65 wpi) from SIV-infected and treated monkeys (MM491, 
MM499, MM528, and MM530) were assessed as described in the legend to Fig. 1. (A) 
Nucleotide substitutions per site are shown. The statistical significance of differences 
between substitution numbers was evaluated by Student’s t-test using GraphPad Prism. 
*p < 0.05; **p < 0.001; ***p < 0.0001; NS, p > 0.05. (B) Nucleotide substitutions per 
annum are shown. *p < 0.001; **p > 0.05. 
Fig. 3. 
 Phylogenetic relationship of env sequences from treated (MM530) and 
untreated (MM521) SIV-infected animals. Sequences of the entire env gene from both 
animals were subjected to phylogenetic analysis. Phylogenetic trees were constructed 
using the Maximum Likelihood method (12). Open circles, sequences in the plasma of 
MM530 at 8 wpi; closed circles, those from the MLN of MM530 at 65 wpi; open 
triangles, those from plasma of MM521 at 8 wpi; closed triangles, those from plasma of 
MM521 at 18 wpi; open inverse triangles, those from plasma of MM521 at 42 wpi; 
closed inverse triangles, those from plasma of MM521 at 68 wpi; closed rectangles, 
those from MLN of MM521 at 68 wpi. The scale represents a genetic distance 
equivalent to 0.002 substitutions per site. The corresponding sequence of SIVmac251 












 Phylogenetic relationships of env sequences from treated and untreated 
animals. Sequences were subjected to phylogenetic analysis as described in the legend 
to Fig. 3. Sequences from MM521 (untreated) and (A) MM491 (treated), (B) MM499 
(treated), and (C) MM528 (treated) are shown. Phylogenetic trees generated using the 
sequences from an individual animal are also shown (D, MM521; E, MM491; F, 
MM499; G, MM528; and H, MM530). Open circles, sequences in the plasma of treated 
animals at 8 wpi; closed circles, those from MLN of treated animals at the completion 
of cART; open triangles, those from plasma of MM521 at 8 wpi; closed triangles, those 
from plasma of MM521 at 18 wpi; open inverse triangles, those from plasma of 
MM521 at 42 wpi; closed inverse triangles, those from plasma of MM521 at 68 wpi; 
closed rectangles, those from MLN of MM521 at 68 wpi. The scale represents a genetic 
distance equivalent to 0.002 substitutions per site. The corresponding sequence of 
SIVmac251 32H (GenBank accession no. D01065) was employed as an outgroup. 
